HC Wainwright Analysts Increase Earnings Estimates for ARTV

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – HC Wainwright increased their Q1 2025 EPS estimates for Artiva Biotherapeutics in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

Other analysts have also recently issued reports about the stock. Wedbush restated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday. Cantor Fitzgerald decreased their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Trading Down 10.7 %

ARTV stock opened at $3.16 on Friday. Artiva Biotherapeutics has a 52 week low of $3.15 and a 52 week high of $17.31. The company has a fifty day simple moving average of $4.71 and a two-hundred day simple moving average of $9.23.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in Artiva Biotherapeutics in the third quarter worth about $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Artiva Biotherapeutics in the fourth quarter worth approximately $52,000. Wells Fargo & Company MN lifted its stake in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the last quarter. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at $135,000. Finally, JPMorgan Chase & Co. bought a new position in Artiva Biotherapeutics in the 3rd quarter valued at $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.